Incidence of infections in patients with status epilepticus requiring intensive care and effect on resource utilization

Anaesthesia and Intensive Care

Volumn 34, Issue 5, 2006, Pages 639-644

  Ala Kokko, T I ^a   Saynajakangas P ^b   Laurila, P ^a   Ohtonen, P ^a   Laurila, J J ^a   Syrjala H ^a  

^a UNIVERSITY OF OULU   (Finland)

^b Department of Anaesthesiology   (Finland)

Author keywords

Critical care; Epilepsy; Infection; Intensive care; Treatment

Indexed keywords

DIAZEPAM; DOBUTAMINE; DOPAMINE; FOSPHENYTOIN SODIUM; LORAZEPAM; MIDAZOLAM; NORADRENALIN; PROPOFOL; SEDATIVE AGENT; THIOPENTAL;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DISEASE SEVERITY; EPILEPTIC STATE; HEALTH CARE UTILIZATION; HOSPITAL INFECTION; HUMAN; INFECTION RATE; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD; NURSING; RETROSPECTIVE STUDY; SEDATION; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33750605599     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0603400509     Document Type: Article

References (23)

1. Alldredge BK, Gelb AM, Isaacs M et al. A comparison of lorazepam, diazepam and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631-637.
2. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205-210.
3. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 2003; 211:37-41.
4. Kälviäinen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs 2005; 19:759-768.
5. Claassen J, Hirsch L, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43:146-153.
6. Lawn N, Wijdicks EFM. Status epilepticus: a critical review of management options. Can J Neurol 2002; 29:206-215.
7. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120:2059-2093.
8. Kress HG, Segmuller R. Intravenous anesthetics and human neutrophil granulocyte motility in vitro. Anaesthesist 1987; 36:356-361.
9. Forbes AR, Gasu G. Depression of lung mucociliary clearance by thiopentone and halothane. Anesth Analg 1979; 58:387-389.
10. Devlin EG, Clarke RS, Mirakhur RK, McNeill TA. Effect of four i.v. induction agents on T-lymphocyte proliferation to OHA in vitro. Br J Anaesth 1994; 73:315-317.
11. Shafer SQ, Brust JC, Healton EB, Mayo JB. Hospital acquired morbidity on a neurology service. J Natl Med Assoc 1993; 85:31-35.
12. Dettenkofer M, Ebner W, Els T et al. Surveillance of nosocomial infections in neurology intensive care unit. J Neurol 2001; 248:959-964.
13. Keene AR, Cullen DJ. Therapeutic intervention scoring system: update 1983. Crit Care Med 1983; 11:1-3.
14. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120-122.
15. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140.
16. Prasad A, Worrall BB, Bertram EH, Bleck T. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380-386.
17. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274:639-644.
18. George DL, Falk PS, Umberto Meduri G et al. Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. Clin Infect Dis 1998; 27:463-470.
19. Mevio E, Benazzo M, Quaglieri S, Mencherini S. Sinus infection in intensive care patients. Rhinology 1996; 34:232-236.
20. Holzapfel L, Chastang G, Bohe J, Piralla B, Coupry A. A randomized study assessing the systematic search for maxillary sinusitis in nasotrahceally mechanically ventilated patients. Influence on nosocomial maxillary sinusitis on the occurrence of ventilation. Am J Respir Crit Care Med 1999; 159:695-701.
21. Rossetti A, Logroscino G, Bromfiels EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62:1698-1702.
22. Parviainen I, Uusaro A, Kalviainen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med 2006; 32:1075-1079.
23. Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopentone in the treatment of refractory status epilepticus in intensive care unit. Neurology 2002; 59:1249-1251.